

Press Release

Stockholm, 5 June 2025

Camilla Oldgren Appointed New CEO of GBA Key2Compliance

GBA Key2Compliance AB is pleased to announce the appointment of Camilla Oldgren as its new Chief Executive Officer (CEO), effective June 1, 2025.

Camilla brings over 30 years of experience in the life sciences industry, with deep expertise in pharmaceuticals, medical devices, and consulting services. Her professional journey spans executive leadership in established companies as well as advisory roles helping businesses navigate growth and transformation.

Most recently, Camilla led her consultancy firm, CJ Oldgren AB, where she supported companies in establishing operations, executive management, and strategic scaling. Prior to that, she served as CEO of Immuned AB, a global provider of customized non-clinical analytical services for life science companies.

In addition to her executive roles, Camilla is an active mentor and business coach leveraging her expertise to help startups scale and commercialize innovative life science solutions.

“We are delighted to welcome Camilla Oldgren to GBA Key2Compliance. Her leadership experience and industry insights are a tremendous asset to our team and to the clients we serve globally. We look forward to working together to further strengthen our role as a trusted partner for companies in the medical device, IVD, and pharmaceutical sectors,” says Laura Garcia Baglietto EVP Medical Devices & Environment International GBA Group.

We would also like to extend our heartfelt thanks to Jan Hellqvist, who has successfully led GBA Key2Compliance in recent years. We are pleased that he will continue with the company as Senior Commercial Advisor, GBA Group Medical Devices.

About GBA Key2Compliance

GBA Key2Compliance is a trusted partner offering expert consulting and specialized training to companies in the Medical Device, IVD, and Pharmaceutical sectors. With a team of over 70 dedicated professionals, we support our clients from early development through to market launch and beyond.

Since January 16, 2024, GBA Key2Compliance has been a part of the GBA Group, a leading European network for laboratory and consulting services. This partnership expands our capabilities across the entire value chain — from preclinical development and clinical trials to quality assurance and production release — ensuring even more comprehensive, efficient, and regulatory-compliant support for our clients.

www.key2compliance.com

www.gba-group.com

Please direct any queries to:

GBA Key2Compliance

Terese Hedin, Marketing Director

terese.hedin@key2compliance.com